2012-10-10 01:06:58 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Lung Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Disease. Lung Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated

disease.


Full Report Details at
- www.fastmr.com/prod/468471_lung_disease_pipeline_review_h2_2012. ..


Scope

* A snapshot of the global therapeutic scenario for Lung Disease.
* A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Lung Disease pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Lung Disease.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Lung Disease pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lung Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Lung Disease
Lung Disease Therapeutics under Development by Companies
Lung Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Lung Disease Therapeutics - Products under Development by Companies
Lung Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Lung Disease Therapeutics Development
Novartis AG
Pharmaxis Ltd.
AGI Therapeutics plc
ProtAffin Biotechnologie AG
Nostrum Pharmaceuticals, LLC
Pulmatrix, Inc.
Mondobiotech Holding AG
PharmaIN Corporation
Lung Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DasKloster-008001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXS-4206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
letrozole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGI-350 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGC-VIP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dapsone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lung Disease Therapeutics - Drug Profile Updates
Lung Disease Therapeutics - Discontinued Products
Lung Disease Therapeutics - Dormant Products
Lung Disease - Product Development Milestones
Featured News & Press Releases
Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants
Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease
Jan 02, 2012: Commonly Used Blood Pressure Drug Prevents Smoking-related Lung Damage In Mice
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Lung Disease, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468471&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.